Development and assessment of innovative models for biopharmaceutical evaluation
In the treatment of diseases involving dysregulation of the immune system, such as cancer and autoimmune diseases, the focus is increasingly on therapies that modulate the immune system. To enable adequate testing of such immunomodulatory therapeutic approaches already in the non-clinical phase, suitable test systems have to be developed and adapted. This development, aimed at improving the transferability of preclinical safety and efficacy data to first-in-human studies, is at the focus of the "Immune Safety Avatar" platform, imSAVAR for short, funded by the Innovative Medicines Initiative (IMI).
- To the ImSAVAR website
- Press release of Dec 3, 2019: Making novel therapeutics safer: Fraunhofer ITEM participates in an EU project to develop innovative model systems for the evaluation of immunomodulatory therapeutics
- R&D expertise Malignant disease
- Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD (cimd.fraunhofer.de)